Redwood Investments LLC Buys 56,788 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Redwood Investments LLC boosted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 25.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 282,264 shares of the company’s stock after buying an additional 56,788 shares during the period. Omnicell accounts for 1.8% of Redwood Investments LLC’s investment portfolio, making the stock its 7th largest position. Redwood Investments LLC owned 0.68% of Omnicell worth $24,283,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Whittier Trust Co. acquired a new position in shares of Omnicell in the 2nd quarter valued at $26,000. Parallel Advisors LLC acquired a new position in shares of Omnicell in the 1st quarter valued at $28,000. Nisa Investment Advisors LLC lifted its stake in shares of Omnicell by 125.0% in the 1st quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock valued at $44,000 after purchasing an additional 300 shares during the last quarter. Manchester Capital Management LLC acquired a new position in shares of Omnicell in the 1st quarter valued at $49,000. Finally, Financial Gravity Wealth Inc. acquired a new position in shares of Omnicell in the 1st quarter valued at $50,000. 97.37% of the stock is currently owned by institutional investors.

OMCL traded down $0.49 during mid-day trading on Wednesday, hitting $69.13. 7,320 shares of the stock were exchanged, compared to its average volume of 683,229. The firm’s fifty day moving average price is $78.69. Omnicell, Inc. has a 1-year low of $56.96 and a 1-year high of $92.59. The company has a current ratio of 2.03, a quick ratio of 1.54 and a debt-to-equity ratio of 0.10. The company has a market cap of $2.94 billion, a P/E ratio of 45.14, a PEG ratio of 2.32 and a beta of 1.11.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.51 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.04. Omnicell had a return on equity of 11.85% and a net margin of 5.70%. The company had revenue of $217.40 million for the quarter, compared to the consensus estimate of $214.13 million. During the same quarter in the prior year, the business earned $0.46 EPS. Omnicell’s revenue was up 15.2% on a year-over-year basis. Sell-side analysts anticipate that Omnicell, Inc. will post 2.05 EPS for the current year.

In other Omnicell news, Chairman Randall A. Lipps sold 5,000 shares of the company’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $70.30, for a total transaction of $351,500.00. Following the sale, the chairman now owns 140,506 shares in the company, valued at approximately $9,877,571.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Dan S. Johnston sold 9,929 shares of the company’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $85.47, for a total value of $848,631.63. Following the sale, the executive vice president now owns 31,505 shares in the company, valued at approximately $2,692,732.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,375 shares of company stock worth $3,291,918. 2.77% of the stock is owned by company insiders.

Several equities analysts have recently commented on OMCL shares. TheStreet lowered Omnicell from a “b” rating to a “c+” rating in a research note on Thursday, April 25th. BidaskClub lowered Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, June 27th. Craig Hallum raised Omnicell from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Friday, July 26th. Benchmark increased their target price on Omnicell from $82.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Finally, ValuEngine lowered Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 12th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $79.11.

About Omnicell

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Recommended Story: Understanding debt-to-equity ratio in fundamental analysis

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.